FRONTIER-3: a randomised phase 2a study to investigate tozorakimab, an anti-interleukin-33 monoclonal antibody, in early-onset asthma

By afschroeder • February 26, 2026

Corren J, Reid F, Moate R, Jimenez E, Sadiq MW, Williams A, Rytelewski M, Cameron-Christie S, Muthas D, Georgi B, Brooks D, Lindqvist E, Kell C, Platt A, Belvisi MG, Pandya H. FRONTIER-3: a randomised phase 2a study to investigate tozorakimab, an anti-interleukin-33 monoclonal antibody, in early-onset asthma. ERJ Open Res. 2026 Feb 23;12(1):00183-2025. doi: 10.1183/23120541.00183-2025. PMID: 41736737; PMCID: PMC12926823.

Tags: Allergy & Immunology, General Internal Medicine, Publications

Delayed Hypersensitivity to Iodinated Contrast: A Rare Case of Iododerma and Successful Strategy for Readministration

Truong T, Tsai M, Ahn TS, Anderson L. Delayed Hypersensitivity to Iodinated Contrast: A Rare Case of Iododerma and Successful Strategy for Readministration. Cureus. 2026[...]

A Cautionary Tale: Urticaria and Angioedema As Presenting Signs of Lymphoproliferative Disorders

Kafashzadeh D, Kachru R. A Cautionary Tale: Urticaria and Angioedema As Presenting Signs of Lymphoproliferative Disorders. Cureus. 2026 Apr 9;18(4):e106738. doi: 10.7759/cureus.106738. PMID: 42109948; PMCID:[...]

Sex does not modify prediction of asthma attacks by clinical risk factors and Type-2 biomarkers

Riemann S, Meulmeester FL, Mailhot-Larouche S, Ramakrishnan S, Wechsler ME, Corren J, Diver SE, Brightling CE, Castro M, Hanania NA, Jackson DJ, Martin N, Laugerud[...]